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IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary
progressive MS. The association between disease-modifying treatments (DMTs), and this
conversion has rarely been studied and never using a validated definition.
OBJECTIVE To determine the association between the use, the type of, and the timing of DMTs
with the risk of conversion to secondary progressiveMS diagnosedwith a validated definition.
DESIGN, SETTING, AND PARTICIPANTS Cohort studywith prospective data from68 neurology
centers in 21 countries examining patients with relapsing-remitting MS commencing DMTs
(or clinical monitoring) between 1988-2012 with minimum 4 years’ follow-up.
EXPOSURES The use, type, and timing of the following DMTs: interferon beta, glatiramer
acetate, fingolimod, natalizumab, or alemtuzumab. After propensity-score matching, 1555
patients were included (last follow-up, February 14, 2017).
MAIN OUTCOME ANDMEASURE Conversion to objectively defined secondary progressiveMS.
RESULTS Of the 1555 patients, 1123 were female (mean baseline age, 35 years [SD, 10]).
Patients initially treated with glatiramer acetate or interferon beta had a lower hazard of
conversion to secondary progressive MS thanmatched untreated patients (HR, 0.71; 95% CI,
0.61-0.81; P < .001; 5-year absolute risk, 12% [49 of 407] vs 27% [58 of 213]; median
follow-up, 7.6 years [IQR, 5.8-9.6]), as did fingolimod (HR, 0.37; 95% CI, 0.22-0.62; P < .001;
5-year absolute risk, 7% [6 of 85] vs 32% [56 of 174]; median follow-up, 4.5 years [IQR,
4.3-5.1]); natalizumab (HR, 0.61; 95% CI, 0.43-0.86; P = .005; 5-year absolute risk, 19% [16 of
82] vs 38% [62 of 164]; median follow-up, 4.9 years [IQR, 4.4-5.8]); and alemtuzumab (HR,
0.52; 95% CI, 0.32-0.85; P = .009; 5-year absolute risk, 10% [4 of 44] vs 25% [23 of 92];
median follow-up, 7.4 years [IQR, 6.0-8.6]). Initial treatment with fingolimod, alemtuzumab,
or natalizumabwas associated with a lower risk of conversion than initial treatment with
glatiramer acetate or interferon beta (HR, 0.66; 95% CI, 0.44-0.99; P = .046); 5-year
absolute risk, 7% [16 of 235] vs 12% [46 of 380]; median follow-up, 5.8 years [IQR, 4.7-8.0]).
The probability of conversion was lower when glatiramer acetate or interferon beta was
started within 5 years of disease onset vs later (HR, 0.77; 95% CI, 0.61-0.98; P = .03; 5-year
absolute risk, 3% [4 of 120] vs 6% [2 of 38]; median follow-up, 13.4 years [IQR, 11-18.1]). When
glatiramer acetate or interferon beta were escalated to fingolimod, alemtuzumab, or
natalizumabwithin 5 years vs later, the HRwas 0.76 (95% CI, 0.66-0.88; P < .001; 5-year
absolute risk, 8% [25 of 307] vs 14% [46 of 331], median follow-up, 5.3 years [IQR], 4.6-6.1).
CONCLUSIONS AND RELEVANCE Among patients with relapsing-remittingMS, initial treatment
with fingolimod, alemtuzumab, or natalizumabwas associated with a lower risk of conversion
to secondary progressive MS vs initial treatment with glatiramer acetate or interferon beta.
These findings, considered along with these therapies’ risks, may help inform decisions about
DMT selection.
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M ultiple sclerosis (MS) is among the most commoncauses of disability in young adults. Eighty-fivepercent of patients present with the relapsing-
remitting form for which several immunomodulatory
disease-modifying therapies (DMTs) reduce relapse rates
and disability accumulation.1-5 Within 2 decades of onset,
80% of untreated patients with relapsing-remitting MS con-
vert to a phase of sustained disability accrual termed sec-
ondary progressive multiple sclerosis.6 This phase is
responsible for much of the disease’s negative physical, psy-
chological, and societal effects.
Until recentlyno rigorousdefinitionof secondaryprogres-
siveMS existed, leading to varying criteria and contradictory
results from 1 randomized trial extension7 and 7 observa-
tional studies8-14 that predominantly examined the associa-
tion of interferon beta or glatiramer acetate with conversion
to secondary progressive MS.
Using a recently publishedvalidateddefinitionof second-
ary progressiveMS,15 the rate of conversion to secondary pro-
gressiveMSwas examinedbetween (1) differentDMTs and an
untreated cohort; (2) fingolimod, alemtuzumab, or natali-
zumab vs glatiramer acetate or interferon beta; and (3) treat-
ment commencement or escalation within vs after 5 years of
disease onset.
Methods
Ethical approval was granted by the Melbourne Health Hu-
man Research Ethics Committee and by each site’s institu-
tional review board. All enrolled patients providedwritten or
verbal consent, in accordance with local regulations.
Patients and Inclusion Criteria
This international observational cohort study used prospec-
tivelycollectedclinicaldata from3sources (all accessed inFeb-
ruary 2017). Untreated patients were selected from the neu-
roinflammatory service database at theUniversityHospital of
Wales, a tertiary referral center inSoutheastWales.Clinicaldata
were initially collectedaspart of a cross-sectional study16 then
through annual or semiannual appointments. Treated pa-
tients were identified from MSBase, an observational cohort
study collecting real-world data frompatientswithMS across
105 centers in 29 countries (Figure 1).17 Additional patients
treated with alemtuzumab were identified from 5 European
non-MSBase centers using alemtuzumab before it was
licensed18 (Bristol, Cardiff, Swansea, Dublin, and Dresden).
Within MSBase, glatiramer acetate or interferon beta, fin-
golimod,andnatalizumabhadsufficientpatientnumberswith
more than 4 years of receiving treatment follow-up (whereas
teriflunomideanddimethyl-fumaratedidnot, so theywerenot
included). The 4-year minimum follow-up period repre-
sented the longest follow-up without excluding the majority
of patients in MSBase who were treated with natalizumab or
fingolimod. Datawere subject to rigorous data-quality proce-
dures (eTable 1 in the Supplement).
For inclusion, patients needed to have been classified
as having relapsing-remitting MS (clinically definite MS19)
at baseline, had the complete MSBase minimum data set
(sex, date of birth, date of clinical onset, and dates of
relapses),20 had at least 1 Expanded Disability Status Scale21
(EDSS) score within 6 months before baseline, and had at
least 2 EDSS scores after baseline (1 to detect disability pro-
gression and another to confirm the increase later, see defi-
nition below). Patients stopping their initial therapy within
6 months were excluded because some drugs require 6
months to take full effect.22 The untreated cohort received
no DMTs, even briefly. The DMT dose, frequency, and
timing followed published protocols18,23: alemtuzumab
(12-24 mg intravenous once per day for 5 days [cycle 1] or for
3 days [cycle 2 or more]); interferon beta (30-250 μg subcu-
taneous or intramuscular injections administered between
every other day to every other week); glatiramer acetate
(20 mg subcutaneous injection once per day); fingolimod
(0.5 mg oral once per day); and natalizumab (300 mg intra-
venously every 4 weeks). Given its administration schedule,
quantifying the duration of alemtuzumab treatment effec-
tiveness is challenging: first, the published period of
reduced CD4 lymphocyte cell count (35 months/cycle24) was
used, and then a sensitivity analysis using the median
period to retreatment (7 years25) was performed. If patients
received multiple DMTs, the first was used as the DMT
under study (except when comparing early vs late escala-
tion from glatiramer acetate or interferon beta to fin-
golimod, alemtuzumab, or natalizumab). Patients subse-
quently receiving different DMTs were excluded from
analyses of single drugs vs untreated patients but were
included in all other analyses. Patients receiving therapies
at any time during the study period that were unlicensed
were excluded (mitoxantrone, cladribine, rituximab, ocreli-
zumab, siponimod, or autologous stem cell transplant).
Although ocrelizumab and cladribine have subsequently
been licensed, there were insufficient numbers meeting
the minimum 4 years’ clinical follow-up criterion within
MSBase to examine individually.
No licensed therapies have shown greater reduction in
relapse rates than natalizumab or alemtuzumab.18 Patients
receiving natalizumab or alemtuzumab who experienced
Key Points
Question Among patients with relapsing-remitting multiple
sclerosis (MS), what is the association between disease-modifying
therapies (DMTs) and the risk of conversion to secondary
progressive multiple sclerosis (MS)?
Findings In this cohort study involving 1555 patients with
relapsing-remitting MS, initial treatment with fingolimod,
natalizumab, or alemtuzumabwas associated with
a lower risk of conversion to secondary progressive MS
compared with interferon beta or glatiramer acetate
(hazard ratio, 0.66).
Meaning These findings, considered along with the risks
associated with these therapies, may help inform decisions
regarding disease-modifying treatment selection for patients
with relapsing-remitting MS.
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relapses or disability progression in this study were there-
fore already at the therapeutic ceiling of treatment. This was
replicated for patients receiving glatiramer acetate or inter-
feron beta (in all analyses) by restricting inclusion to
patients treated and followed up before fingolimod, ale-
mtuzumab, or natalizumab became available, preventing
the exclusion of patients who might have been prescribed
these more potent therapies as a first-line or escalation
therapy during follow-up and thereby preventing selection
bias toward milder disease among the glatiramer acetate or
interferon beta group. (During this period, mitoxantrone
was occasionally used as escalation therapy for particularly
aggressive disease: to ensure the glatiramer acetate or inter-
feron beta group was not biased toward milder disease, sen-
sitivity analyses including these patients were performed).
Consistent with previous work,18 patients participating in
clinical trials were excluded because their trial treatment
assignation was not documented within MSBase, and trial
EDSS frequencies often differ to clinical practice. Patients
with previous stem cell transplants were also excluded.
Study Design
To examine whether individual DMTs were associated with
delayed or reduced conversion to secondary progressive
MS, matching and analyses were repeated 4 times compar-
ing untreated patients with those receiving initial treatment
with (1) glatiramer acetate or interferon beta, (2) fingolimod,
(3) natalizumab, or (4) alemtuzumab. In these analyses, the
date of DMT commencement acted as the baseline date for
treated patients. For untreated patients, the baseline date
was the visit date when clinical and demographic para-
meters (calculated at each visit and quantified using the
propensity score) most closely matched the corresponding
baseline values of individual treated patients.
Fingolimod,4 alemtuzumab,5 and natalizumab26 confer
greater reductions in relapse rate thanglatiramer acetateor in-
terferon beta. To examine whether they are associated with
different effects on conversion to secondary progressive MS,
patients receiving 1 of the 3 drugs as their initial DMT were
matched and compared with patients initially treated with
glatiramer acetate or interferon beta.
To examine the association between timing of DMT
commencement and conversion to secondary progressive
MS, patients initially treated with glatiramer acetate or inter-
feron beta within 5 years of disease onset were matched
and compared with those initially treated after 5 years. For
patients treated within 5 years, the baseline was set at DMT
commencement. For all patients treated after 5 years, the
Figure 1. MSBase Study Design of PatientsWithMultiple Sclerosis (MS)
34 765 Excluded
14 001 Did not receive DMT during follow-up in MSBase cohort
7171 <3 EDSS scores (including 1 before baseline)
6251 <4 y clinical follow-up (3364 started DMT within 4 y of data
extract; 2887 missing data)
3679 Not classified as relapsing-remitting MS at baseline
(2676  primary progressive MS; 1003 secondary progressive MS)
1996 Received ≥1 DMTs but each treatment <6 moa
1633 Received ineligible treatmentb
34 Participated in a randomized clinical trial
57 Treated with alemtuzumab
only
100 Treated with natalizumab
only
88 Treated with fingolimod
only
3715 Treated with glatiramer
acetate only
92 Treated with alemtuzumab
at anytime
1182 Treated with natalizumab
at anytime
605 Treated with fingolimod
at anytime
8353 Treated with glatiramer
acetate at anytime
275 Untreated
431 Patients treated and
followed up before
fingolimod, alemtuzumab,
and natalizumab were
available for escalation
9452 Eligible for matching
44 217 Patients with MS were assessed
for eligibility
43 048 MSBase
1091 Untreated
78 Non-MSBase alemtuzumab
a When recorded, reasons for stopping were included: 341 due to intolerance;
65, inconvenience; 42, pregnancy (or planned pregnancy); 65, inefficacy
(relapses, EDSS progression, magnetic resonance imaging activity, or patient
perception of lack of improvement); and 15, nonadherence.
b Ineligible treatmentsweredefinedas treatments not licensed for relapsing-
remittingMSat the timeof the studyperiod (mitoxantrone, cladribine, rituximab,
ocrelizumab, siponimod, or autologous stem-cell transplant).
DMT indicatesdisease-modifying therapy; EDSS, ExpandedDisability Status Scale.
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baseline was set at a visit within 5 years of symptom onset,
before therapy began, incorporating the period from base-
line to treatment initiation into the follow-up. The date of
this visit was identified by extracting the matching variables
at each eligible visit within 5 years of symptom onset, then
using a matching process to identify when these variables
most closely matched those of a patient treated within 5
years. By handling treatment exposure as a time-dependent
variable, the analyses accounted for immortal time bias,
including the untreated time from baseline to treatment ini-
tiation in the group treated after 5 years. This technique was
repeated when comparing escalation from glatiramer acetate
or interferon beta to fingolimod, alemtuzumab, or natali-
zumab within vs after 5 years of disease onset.
Outcome
The outcome in all analyses was conversion to secondary
progressive MS based on an objective definition15 without
functional scores: patients required an EDSS increase (if the
EDSS score was 5.5 or less, an increase of 1 point was
required; if the EDSS score was more than 5.5, an increase of
0.5 points was required). This EDSS increase had to (1) occur
in the absence of a relapse, (2) be confirmed at the next
appointment (≤3 months later), and (3) the resultant EDSS
score had to be 4 or more.15
Matching
Using the MatchIt package27 (v2.4-22), the propensity of
treatment was estimated using a multivariable logistic
regression model using baseline age, sex, annualized
relapse rate in the year prior to baseline, EDSS score, and
disease duration.
To minimize the difference in proportions of time taking
therapy during follow-up in the glatiramer acetate or inter-
feron beta vs fingolimod, alemtuzumab, or natalizumab
analysis, patients were additionally matched on the propor-
tion of time taking therapy during the median follow-up
period (first 5.8 years). Patients in the early vs late escalation
from glatiramer acetate or interferon beta to fingolimod, ale-
mtuzumab, or natalizumab analyses were also matched on
disease duration at the time of starting glatiramer acetate or
interferon beta plus the individual therapy to which they
were escalated.
To increase matching precision,18,28 patients were
matched in a variable matching ratio (10:1 to 1:1) by nearest
neighbor matching using the optimal caliper (0.1 standard
deviations of the propensity score).29-31 When treatment ini-
tiation was not used as the baseline (the late group in the
early vs late glatiramer acetate or interferon beta and escala-
tion analyses; and the untreated group in all untreated
analyses), any visit could serve as baseline (to optimize
matching). A single patient could therefore be used multiple
times in 1 analysis and across analyses. To account for this,
replacement was permitted in these matching models. All
subsequent models were weighted to account for the vari-
able matching ratio (see below). Each patient’s follow-up
was censored to the shortest of the 2 follow-up times from
each set, resulting in identical follow-up durations between
groups. Sets in which either patient subsequently had fewer
than 2 EDSS scores following baseline were excluded.
Statistical Analysis
All analyses were performed using the survival package
(v3.3.1) in R. Setwise weighted conditional proportional haz-
ards models (Cox) clustered for matched patient sets exam-
ined the proportions of patients free from conversion to sec-
ondary progressive MS. All models were adjusted for EDSS
frequency plus any variables showing residual imbalance fol-
lowing matching (as denoted by a standardized difference,
quantified by a Cohen d value, ≥0.2,32 which indicates <92%
overlap between the groups). The weights were calculated as
the inverse of the number of times a patient was included in
an analysis to account for the variable matching ratio. The
models comparing (1) glatiramer acetate or interferon beta
with fingolimod, alemtuzumab, or natalizumab; (2) early vs
late glatiramer acetate or interferon beta; and (3) early vs late
escalation from glatiramer acetate or interferon beta to fin-
golimod, alemtuzumab, or natalizumab were also adjusted
for the proportion of time taking therapy during the entire
postbaseline setwise-censored follow-up. The Schoenfeld
global test33 was used to detect violation of the proportional
hazards assumption. When violated, Weibull accelerated
failure-time regression models were used. To estimate the
conditional hazard ratio (HR), robust estimation of variance
based on the Huber sandwich estimator was used. The Efron
approximation was used to resolve tied survival times.
Graphs were censored at the latest point that each group con-
tained at least 10 patients or less than 10% of the original
group, whichever came first. The percentage of patients who
had converted to secondary progressive MS are presented at
5 years and the last year before censor in the text. Two-sided
significance testing was used. Results were considered sig-
nificant at the P < .05 level. Because there was no adjustment
for multiple comparisons, secondary analyses should be
interpreted as exploratory.
Results
A total of 44217 patients with MS (1091 from the Welsh un-
treated cohort, 43048 from MSBase, and 78 alemtuzumab-
treated patients from non-MSBase centers) were assessed
for eligibility (Figure 1). To avoid informed censoring bias, the
glatiramer acetate or interferon beta groups were limited to
those treated and followed-up before fingolimod, ale-
mtuzumab, or natalizumab became available for escalation
(baseline years, 1996-1998; Table 1 and Table 2). Following
exclusion of ineligible patients (Figure 1), the matching pro-
cess then matched 1555 patients from 68 centers in 21 coun-
tries (eTable 3 in the Supplement): 230 from the Welsh
untreated cohort, 1272 from MSBase, and 53 alemtuzumab-
treated patients from non-MSBase centers (Table 1, Table 2,
and eTables 3-4 in the Supplement). Matching coefficients
and EDSS scores after conversion to secondary progressive
MS are shown in eTables 5 and 6 in the Supplement, respec-
tively. The assumption of proportionality was not met in 6 of
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9 analyses (requiring Weibull accelerated failure-time regres-
sion models). Patients excluded due to missing data were
slightly older with higher baseline EDSS scores (eTable 7 in
the Supplement)
Compared with no treatment, treatment with each
included therapy was associated with a significantly lower
probability of converting to secondary progressive MS. For
patients initially treated with glatiramer acetate or interferon
beta (n = 407), the HR was 0.71 (95% CI, 0.61-0.81; P < .001)
compared with untreated patients (n = 213), median censored
follow-up 7.6 years (interquartile range [IQR], 5.8-9.6 years),
at 5 years, 12% vs 27%, respectively, had converted, and at 11
years, 47% vs 57% had converted (Figure 2A). Fewer patients
initially treated with fingolimod (n = 85) converted compared
with untreated patients (n = 174) (HR, 0.37; 95% CI, 0.22-
0.62; P < .001; median censored follow-up, 4.5 years; IQR,
4.3-5.1 years), at 5 years, 7% vs 32%, respectively, had con-
verted, and at 6 years, 7% vs 39% had converted (Figure 2B).
Conversion to secondary progressive MS was also signifi-
cantly lower for patients initially treated with natalizumab
(n = 82) compared with untreated patients (n = 164) (HR,
0.61; 95% CI, 0.43-0.86; P = .005; median censored follow-
up, 4.9 years; IQR, 4.4-5.8 years), at 5 years, 19% vs 38%
respectively had converted, while at 6 years, 34% vs 48% had
converted (Figure 2C). The hazard ratio for converting to sec-
ondary progressive MS was significantly lower for patients
initially treated with alemtuzumab (n = 44) compared with
untreated patients (n = 92) (HR, 0.52; 95% CI, 0.32-0.85;
P = .009; median censored follow-up, 7.4 years; IQR, 6.0-8.6
years), at 5 years, 10% vs 25%, respectively, had converted,
whereas at 8 years 21% vs 41% had converted (Table 1 and
Figure 2D).
The probability of converting to secondary progressive
MS was significantly lower for patients initially receiving
glatiramer acetate or interferon beta within 5 years of disease
onset (n = 120) compared with matched patients treated with
glatiramer acetate or interferon beta later (n = 38) (HR, 0.77;
95% CI, 0.61-0.98; P = .03; median censored follow-up, 13.4
years; IQR, 11-18.1 years). Five years after baseline, 3% vs 6%,
respectively, had converted to secondary progressiveMS, and
Figure 2. Comparison of the Cumulative Hazard of Conversion to Secondary ProgressiveMultiple Sclerosis in Untreated Patients
vsMatched Treated Patients Compared by Initial Treatment
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at 17 years 29% vs 47% had converted (Figure 3A). Including
patients who had escalated to mitoxantrone did not materi-
ally alter the results (HR, 0.82; 95% CI, 0.67-1.00; P = .05).
The probability of converting to secondary progressive MS
was significantly lower when initial treatment with glati-
ramer acetate or interferon beta was commenced within 5
years of disease onset (n = 164) compared with untreated
patients (n = 104) (HR, 0.26; 95% CI, 0.15-0.45; P < .001) with
the difference increasing proportionally throughout the 11
years of follow-up (corresponding to 14 years’ disease dura-
tion (Figure 3B). In contrast, the significantly lower probabil-
ity of conversion following initial treatment with glatiramer
acetate or interferon beta commencing 5 to 10 years after dis-
ease onset (n = 95) compared with untreated patients
(n = 158; HR, 0.67;95% CI, 0.51-0.87; P = .003) waned after 5
years of treatment (disease duration, 11.8 years) and disap-
peared at 7.8 years (disease duration, 14.6 years, Figure 3C).
The probability of converting to secondary progressive MS
was significantly lower for patients escalated from glatiramer
acetate or interferon beta to fingolimod, alemtuzumab, or
natalizumab within 5 years of disease onset (n = 307) com-
pared with matched patients escalated later (n = 331) with an
HR of 0.76 (95% CI, 0.66-0.88; P < .001; median censored
follow-up, 5.3 years; IQR, 4.6-6.1 years): at 5 years, 8% vs
14%, respectively, had converted and at 7 years, 14% vs 28%
had converted (Figure 3D). This difference persisted when
the alternative (7-year) definition of alemtuzumab treatment
duration was used in a sensitivity analysis (HR, 0.78; 95% CI,
0.67-0.91; P = .001).
Patients initially receiving fingolimod, alemtuzumab, or
natalizumab (n = 235) had a significantly lower risk of con-
version to secondary progressive MS than matched patients
initially receiving glatiramer acetate or interferon beta
(n = 380) with an HR of 0.66 (95% CI, 0.44-0.99; P = .046;
median censored follow-up, 5.8 years; IQR, 4.7-8.0 years).
At 5 years, 7% vs 12%, respectively, had converted, and at 9
years, 16% vs 27%, respectively, had converted (Figure 4).
This persisted in sensitivity analyses when the alternative
(7-year) definition of alemtuzumab treatment duration was
used (HR, 0.60; 95% CI, 0.39-0.90; P = .01); and when
Figure 3. Comparison of the Cumulative Hazard of Conversion to Secondary ProgressiveMultiple Sclerosis by Timing of Treatment
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patients in the glatiramer acetate or interferon beta group
escalated to mitoxantrone were included (HR, 0.88; 95% CI,
0.84-0.91; P < .001).
Discussion
In this observational cohort study that used prospectively
collected clinical data, initial treatment with fingolimod,
alemtuzumab, or natalizumab was associated with a signifi-
cantly lower risk of conversion to secondary progressive MS
compared with initial treatment with glatiramer acetate or
interferon beta. The risk of conversion was significantly
lower for early treatment than for late treatment: either in
the case of starting glatiramer acetate or interferon beta
within 5 years of disease onset vs later commencement; or
when escalating from glatiramer acetate or interferon beta
to fingolimod, alemtuzumab, or natalizumab within 5 years
of disease onset vs later escalation.
These results suggest that initial treatment with glati-
ramer acetate or interferon beta is associated with reduced
conversion to secondary progressive MS compared with
untreated patients. There is no consensus in the literature.
An intention-to-treat analysis of the study conducted by the
IFNβ Multiple Sclerosis Study Group found no difference in
conversion rates between interferon and placebo 16 years
later, but many patients treated with placebo subsequently
received DMTs.7 Six of 7 observational studies reported
favorable associations between glatiramer acetate or inter-
feron beta and secondary progressive MS conversion, both
individually8-13 and in a meta-analysis.34 The remaining
observational study from British Columbia—the only study to
circumvent immortal time bias35 through treating interferon
exposure as a time-dependent variable (ensuring time before
interferon treatment contributed to the untreated follow-up
time)—found no relationship between interferon exposure
and secondary progressive MS conversion.14 These observa-
tional studies—all published before an objective secondary
progressive MS definition became available15—have highly
heterogeneous methods including variable (or inaccessible)
secondary progressive MS definitions, inconsistent exclusion
of relapse-related disability increases; and variable strategies
for mitigating indication bias (arising from nonrandom treat-
ment exposure), attrition bias (reflecting between-group dif-
ferences in follow-up duration), detection bias (from differ-
ing EDSS frequency during follow-up) and immortal-time
bias.8-14 In observational study designs, propensity score–
based estimators better reflect true differences than nonex-
perimental estimators, such as multivariable regression or
latent variable selection models, given that an overlap exists
between the compared groups.36 In this analysis, matching
with a caliper was used, which is more robust in scenarios
with restricted sample size and strong treatment-selection
processes than unrestricted propensity score-based methods
such as inverse probability of treatment weighting or optimal
full matching.30,31 All models were adjusted for EDSS fre-
quency to mitigate detection bias and setwise censoring of
follow-up duration was used to mitigate attrition bias. To
address the issue of immortal-time bias,35 DMT was treated
as a time-dependent variable. The risk of secondary progres-
sive MS conversion increases with disease duration,6 so time
from MS onset should be considered in evaluations of sec-
ondary progressive MS conversion rates in different treat-
ment scenarios (Table 1, Table 2,and Figure 2). This may have
reduced the strength of the association of natalizumab with
reduction in conversion to secondary progressiveMS because
it was used by many patients with longer disease duration at
baseline than other agents.
Limitations
This study has several limitations. First, given its observa-
tional design, the study is unable to ascribe causality and
cannot distinguish between prevention and delay of conver-
sion to secondary progressive MS. The longest comparison
however showed a favorable association of early (vs later)
glatiramer acetate or interferon beta, enduring to the end of
Figure 4. Comparison of Cumulative Hazard of Conversion to Secondary ProgressiveMultiple Sclerosis
for Initial TreatmentWith Glatiramer Acetate or Interferon Beta vs Fingolimod, Alemtuzumab, or Natalizumab
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follow-up 17 years after baseline (median disease duration
20 years; Figure 3, A). Second, the absence of EDSS func-
tional score subcomponents precluded using the secondary
progressive MS definition with the highest combination of
sensitivity, specificity and accuracy; the definition used in
this study, requiring total EDSS only, has previously been
shown to be associated with a 1% loss of accuracy and 6%
reduction in sensitivity.15 Third, the differing baseline demo-
graphics of each DMT cohort (Table 1) required differing
matched untreated cohorts with differing follow-up dura-
tions; their relative therapeutic effects should therefore not
be compared between analyses (Figure 2A-D). A particular
problem with the fingolimod-untreated comparison was the
inability to eliminate informed censoring bias because
fingolimod-treated patients subsequently escalated to
monoclonal antibody treatment (due to disease activity
while being treated) were excluded (Figure 2B). Such
informed censoring does not affect the comparison between
untreated patients and monoclonal antibodies (because
patients cannot be escalated from these highly-effective
therapies18) nor the untreated comparisons with glatiramer
acetate or interferon beta (for which the inclusion criteria
ensured more potent therapies were not generally available
during the studied epoch). Fourth, the glatiramer acetate or
interferon beta cohorts therefore came from an earlier
period, leading to 10 to 11 years median difference in the
baseline dates of the glatiramer acetate or interferon beta vs
untreated analyses, and 13 years’ median difference in the
analysis comparing glatiramer acetate or interferon beta
with fingolimod, alemtuzumab, or natalizumab. It is pos-
sible that unmeasured changes in care between time
epochs—more specialist nurses, better symptomatic man-
agement, lower thresholds for escalating therapy for
example—may have contributed to differences in secondary
progressive MS conversion rates in these particular analyses.
However, all other analyses (with contemporaneous groups;
≤5 years difference, Table 1 and Table 2) also support early
and aggressive DMT use. The ability to match contempora-
neous untreated patients to those commencing fingolimod,
alemtuzumab, or natalizumab (Table 1) took advantage of
the United Kingdom’s lower DMT uptake rates. The general-
izability of the untreated group to other geographic regions
cannot be guaranteed. Fifth, a large number of patients were
excluded due to ineligibility (Figure 1). At least 65 patients
were excluded through stopping their DMT within 6 months
due to inefficacy (Figure 1). Although a modest number,
their exclusion may have biased the remaining patients pre-
sented for matching toward a relatively milder disease.
Those excluded due to missing data were slightly older with
higher baseline EDSS scores (eTable 7 in the Supplement).
Although the exclusion criteria have made the results more
robust, the resultant unmatched cohorts are, by definition,
unrepresentative of the whole unfiltered cohort. Despite the
stringent matching criteria, 63% to 97% of treated eligible
patients were successfully matched. Beyond lower baseline
relapse rates, the matched cohorts (Table 1) are similar to
those in the original placebo-controlled phase 3 trials inves-
tigating these therapies.1-3 Sixth, some factors were unavail-
able across all cohorts (for example smoking status; lesion
number or brain volume on MRI; drug adherence; or the
presence of oligoclonal bands in cerebrospinal fluid), pre-
cluding their inclusion in matching models. If these vari-
ables differed systematically between the compared groups
and are associated with the risk of secondary progressive MS
conversion, then they might have acted as confounders.
Through the use of an objective secondary progressive MS
definition, any positive bias of outcomes by the clinician
instigating the intervention or escalation should have been
mitigated. Seventh, the assessment of disability (and there-
fore secondary progressive MS conversion) relied on the
EDSS score. Although the most widely used disability mea-
sure, it has high interrater variability at lower scores, limited
sensitivity to cognitive impairment, and, at scores higher
than 3.5, is largely determined by ambulation.37,38 To miti-
gate interrater variability, this published definition of sec-
ondary progressive MS requires EDSS step 4 attainment and
confirmation of EDSS increases on 2 occasions, at least 3
months apart. Eighth, the numbers of patients available in
some analyses was quite small. Despite this, clinically and
statistically significant differences between the groups were
observed. Ninth, while relatively few patients contribute to
the final periods of follow-up in Figure 2, Figure 3, and
Figure 4, the groups diverge before this and the statistics are
heavily weighted toward the left of each figure. Tenth, while
death due to non-MS causes may represent a competing risk,
we were unable to include this in the presented models due
to incomplete reporting. Eleventh, this study did not assess
the risks associated with DMTs, and so the association
between initial fingolimod, alemtuzumab, or natalizumab
use and lower risk of secondary progressive MS conversion—
which is consistent with these therapies’ greater effect on
relapse rates and disability metrics4,5,26—must be considered
in light of their greater risks, administration and monitoring
schedules, and initial costs during the DMT selection process.
Conclusions
Amongpatientswith relapsing-remittingMS, initial treatment
with fingolimod,alemtuzumab,ornatalizumabwasassociated
withalowerriskofconversiontosecondaryprogressiveMScom-
paredwith initial treatmentwithglatirameracetateor interferon
beta.Thesefindings,consideredalongwiththesetherapies’risks,
may help informdecisions about DMT selection.
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